Transdermal buprenorphine: A current overview of pharmacological and clinical data;La buprénorphine transdermique: L'état actuel dans les domaines clinique et pharmacologique

Revue Medicale de Liege

Volumn 63, Issue 11, 2008, Pages 671-676

  Faymonville, M E ^a   Libbrecht, D ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acute pain; Buprenorphine; Chronic pain; Opioids; Transdermal therapeutic system

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; OPIATE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CHRONIC PAIN; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; RESPIRATION DEPRESSION; REVIEW; CHRONIC DISEASE; INTRADERMAL DRUG ADMINISTRATION; PAIN;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; HUMANS; PAIN;

EID: 59249105003     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Coluzzi F, Pappagallo M. - Opioid therapy for chronic noncancer pain : practice guidelines for initiation and maintenance of therapy. National Initiative on Pain Control. Minerva Anestesiol, 2005, 71, 425-433.
2. Kalso E. - Improving opioid effectiveness : from ideas to evidence. Eur J Pain, 2005, 9, 131-135.
3. Sittl R, Nuijten M, Nautrup BP. - Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther, 2006, 28, 1144-1154.
4. Strain EC, Moody DE, Stoller KB, et al. - Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend, 2004, 74, 37-43.
5. McQuay HJ, Moore RA. - Buprenorphine kinetics. In: Foley KM, Inturrisi CE, eds. Advances in Pain Research and Therapy. New York : Raven Press, 1986, 271-279.
6. Huang P, Kehner GB, Cowan A, Liuchen LY. - Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther, 2001, 297, 688-695.
7. Ohtani M, Kotaki H, Sawada Y, Iga T. - Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther, 1995, 272, 505-510.
8. Bullingham RE, Mcquay HJ, Porter EJ, et al. - Sublingual buprenorphine used postoperatively : ten hour plasma drug concentration analysis. Br J Clin Pharmacol, 1982, 13, 665-673.
9. Bullingham RE, Mcquay HJ, Moore A, Bennett MR. - Buprenorphine kinetics. Clin Pharmacol Ther, 1980, 28, 667-672.
10. Budd K. - Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract, 2003, 133, 9-14.
11. McMahon S, Koltzenburg M, eds. - Wall and Melzack's Textbook of Pain, 5th edition. New York. Elsevier Inc, 2005, 444.
12. Budd K. - High dose buprenorphine for postoperative analgesia. Anaesthesia, 1981, 36, 900-903.
13. Dahan A. - Opioid-induced respiratory effects. New data on buprenorphine. Palliative Medicine, 2006, 20, s3-s8.
14. Johnson RE, Fudala PJ, Payne R. - Buprenorphine : considerations for pain management. J Pain Symptom Manage, 2005, 29, 297-326.
15. Freye E, Anderson-Hillemacher A, Ritzdorf I, et al. - Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract, 2007, 7, 123-129.
16. Sittl R, Likar R, Nautrup BP. - Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther, 2005, 27, 225-237.
17. Bohme K. - Buprenorphine in a transdermal therapeutic system- a new option. Clin Rheumatol, 2002, 21, S13-S16.
18. Griessinger N, Sittl R, Likar R. - Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin, 2005, 21, 1147-1156.
19. Niv D, Nemirovsky A, Metzner R, et al. - Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine. Anesth Analg, 1998, 87, 583-586.
20. Nemirovsky A, Chen L, Zelman V, Jurna I. - The anti-nociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine. Anesth Analg, 2001, 93, 197-203.
21. Mercadante S, Villari P, Ferrera P, et al. - Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Management, 2006, 32, 175-179.
22. De Barutell C, Gonzales-Escalada JR. - Efficacy and safety of buprenorphine TDS in conjunction with pral tramadol or morphine as rescue medication in the treatment of 390 patients with chronic pain : A summary of two retrospective Spanish multicenter studies. J Appl Ther Res, 2007, 6, 14-24.
23. Benedetti F, Amanzio M, Casadio C, et al. - Post-operative pain and superficial abdominal reflexes after posterolateral thoracotomy. Ann Thorac Surg, 1997, 64, 207-210.
24. Zenz M, Strumpf M, Trya M. - Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage, 1992, 7, 69-77.
25. Glynn C, Mcquay HJ, Lloyd JW, et al. - Intrathecal buprenorphine for painful muscle spasms in paraplegic patients. Pain, 1984, 18, S341.
26. Omote K, Ohmori H, Kawamata M, et al. - Intrathecal buprenorphine in the treatment of phantom limb pain. Anesth Analg, 1995, 80, 1030-1032.
27. Grond S, et al. - Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain, 1999, 79, 15-20.
28. Arner S, Meyerson BA. - Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain, 1988, 33, 11-23.
29. Bohme K. - Buprenorphine in a transdermal therapeutic system - a new option. Clin Rheumatol, 2002, 21, S13-S16.
30. Haazen L, Noorduin H, Megens A, Meert T. - The constipation inducing potential of morphine and transdermal fentanyl. Eur J Pain, 1999, 3, S9-S15.
31. Cuer JC, Dapoigny M, Ajmi S, et al. - Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol, 1989, 36, 203-204.
32. Martucci C, Panerai AE, Sacerdote P. - Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain, 2004, 110, 385-392.
33. Beilin B, Shavit Y, Hart J, et al. - Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg, 1996, 82, 492-497.
34. Yeager MP, Colcchio TA, Yu CT, et al. - Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology, 1995, 83, 500-508.
35. Sacerdote P, Bianchi M, Gaspani L, et al. - The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg, 2000, 90, 1411-1414.